登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
ClinicalTrials.gov 上登记的一项肺癌开放试验,由上海市胸科医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07549061,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Have histologically or cytologically confirmed NSCLC. (pathology reports from outside institutions are acceptable).
入选标准第 3 条
Have newly diagnosed locally advanced or metastatic NSCLC that is not amenable to curative surgery or radiotherapy according to the AJCC 9th edition staging system.
入选标准第 4 条
Have no prior systemic anticancer therapy for advanced or metastatic disease. Prior neoadjuvant or adjuvant systemic therapy, definitive chemoradiotherapy or radiotherapy is permitted provided that treatment was completed ≥12 months before recurrence.
入选标准第 5 条
Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose and all participants of reproductive potential must agree to use effective contraception from informed consent until 3 months after the last dose of study treatment.
入选标准第 14 条
Any prior systemic antitumour therapy for advanced or metastatic NSCLC, including chemotherapy, immunotherapy, biologic therapy, targeted therapy, or investigational agents. For patients with recurrent disease, prior neoadjuvant or adjuvant systemic therapy, or definitive radiotherapy or chemoradiotherapy, with or without immunotherapy, biologic therapy, or investigational agents, is permitted provided that treatment was completed ≥12 months before documented disease recurrence.
排除标准第 9 条
Pregnancy and lactation Pregnant or breastfeeding women, or women of childbearing potential who are unwilling or unable to use highly effective contraception during the study treatment period and for 3 months after the last dose of study treatment.
排除标准第 24 条
Have an ECOG performance status of 0-2.
入选标准第 6 条
Have no actionable driver oncogene alteration identified by tissue and/or blood-based molecular testing. At a minimum, testing must exclude EGFR sensitising mutations, ALK rearrangements, ROS1 rearrangements, RET fusions, NTRK fusions, KRAS G12C mutations, BRAF V600E mutations, MET exon 14 skipping alterations and other actionable alterations according to current clinical practice and locally available testing. Concurrent MET amplification is permitted provided that the tumour meets the prespecified MET protein overexpression criterion.
入选标准第 7 条
absolute neutrophil count ≥1.5 × 10⁹/L; 2) hemoglobin ≥90 g/L; 3) platelets ≥75 × 10⁹/L; 4) total serum bilirubin ≤1.5 × ULN; 5) AST and ALT ≤3 × ULN, or ≤5 × ULN in patients with liver metastases; 6) serum creatinine <1.5 × ULN. 7) creatinine clearance >50 mL/min, calculated using the Cockcroft-Gault formula.
入选标准第 13 条
Have at least one measurable lesion according to RECIST version 1.1.
入选标准第 11 条
Other malignancies Diagnosis of another malignancy requiring active treatment within the previous 3 years, except for completely resected basal cell carcinoma or squamous cell carcinoma of the skin, or completely resected carcinoma in situ without evidence of recurrence.
排除标准第 12 条
Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, as defined by the following:
排除标准第 16 条
hepatitis B: positive hepatitis B surface antigen (HBsAg) with HBV DNA ≥500 IU/mL;
排除标准第 17 条
hepatitis C: positive HCV antibody with detectable HCV RNA;
排除标准第 18 条
HIV infection: positive HIV antibody;
排除标准第 19 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:怀孕、哺乳与避孕。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07549061,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Provide written informed consent before initiation of any study-specific procedure and be willing and able to comply with study procedures. Be aged ≥18 years. Have histologically or cytologically confirmed NSCLC. (pathology reports from outside institutions are acceptable). Have newly diagnosed locally advanced or metastatic NSCLC that is not amenable to curative surgery or radiotherapy according to the AJCC 9th edition staging system. Have no prior systemic anticancer therapy for advanced or metastatic disease. Prior neoadjuvant or adjuvant systemic therapy, definitive chemoradiotherapy or radiotherapy is permitted provided that treatment was completed ≥12 months before recurrence. Have an ECOG performance status of 0-2. Have no actionable driver oncogene alteration identified by tissue and/or blood-based molecular testing. At a minimum, testing must exclude EGFR sensitising mutations, ALK rearrangements, ROS1 rearrangements, RET fusions, NTRK fusions, KRAS G12C mutations, BRAF V600E mutations, MET exon 14 skipping alterations and other actionable alterations according to current clinical practice and locally available testing. Concurrent MET amplification is permitted provided that the tumour meets the prespecified MET protein overexpression criterion. Have MET protein overexpression, defined as moderate-to-strong (2+ or 3+) MET staining in ≥50% of viable tumour cells by IHC. Have a PD-L1 TPS <50% Have an estimated life expectancy of at least 3 months. Have at least one measurable lesion according to RECIST version 1.1. Have adequate organ function as defined by the following laboratory criteria: absolute neutrophil count ≥1.5 × 10⁹/L; 2) hemoglobin ≥90 g/L; 3) platelets ≥75 × 10⁹/L; 4) total serum bilirubin ≤1.5 × ULN; 5) AST and ALT ≤3 × ULN, or ≤5 × ULN in patients with liver metastases; 6) serum creatinine <1.5 × ULN. 7) creatinine clearance >50 mL/min, calculated using the Cockcroft-Gault formula. Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose and all participants of reproductive potential must agree to use effective contraception from informed consent until 3 months after the last dose of study treatment.排除标准:Exclusion Criteria:
Central nervous system conditions Spinal cord compression or symptomatic, unstable brain metastases requiring urgent local treatment Patients with symptomatic brain metastases may be eligible if definitive local treatment has been completed, corticosteroid therapy has been discontinued, and neurological status has remained stable for at least 2 weeks after completion of definitive treatment and corticosteroid therapy. Asymptomatic brain metastases may be permitted if, in the investigator's judgement, immediate local treatment is not clinically indicated. Prior treatment and medication history Major surgery, including intrathoracic, intra-abdominal, or intrapelvic surgery, within 4 weeks before enrolment, or failure to recover adequately from the effects of previous surgery. Thoracoscopic biopsy and mediastinoscopy are not considered major surgery; patients may be enrolled ≥1 week after these procedures if adequately recovered. Treatment with traditional Chinese medicines or Chinese patent medicines with an antitumour indication within 1 week before the first dose of study treatment. Concomitant treatment with strong CYP3A4 inducers or strong CYP3A4 inhibitors that cannot be discontinued for at least 1 week before initiation of study treatment and avoided during study treatment. Any prior systemic antitumour therapy for advanced or metastatic NSCLC, including chemotherapy, immunotherapy, biologic therapy, targeted therapy, or investigational agents. For patients with recurrent disease, prior neoadjuvant or adjuvant systemic therapy, or definitive radiotherapy or chemoradiotherapy, with or without immunotherapy, biologic therapy, or investigational agents, is permitted provided that treatment was completed ≥12 months before documented disease recurrence. Radiotherapy involving >30% of the bone marrow or radiotherapy with a large treatment field within 4 weeks before the first dose of vebreltinib. Use of any investigational drug within 2 weeks before the first dose of study treatment or concurrent participation in another interventional clinical trial. Other malignancies Diagnosis of another malignancy requiring active treatment within the previous 3 years, except for completely resected basal cell carcinoma or squamous cell carcinoma of the skin, or completely resected carcinoma in situ without evidence of recurrence. Active infection and pulmonary or gastrointestinal conditions Active infection requiring systemic anti-infective treatment within 2 weeks before the first dose of study treatment, including clinically significant pneumonia. Active tuberculosis or other clinically significant uncontrolled infection. Active hepatitis B, hepatitis C, human immunodeficiency virus (HIV) infection, as defined by the following: hepatitis B: positive hepatitis B surface antigen (HBsAg) with HBV DNA ≥500 IU/mL; hepatitis C: positive HCV antibody with detectable HCV RNA; HIV infection: positive HIV antibody; History of interstitial lung disease, drug-induced interstitial lung disease, or radiation pneumonitis requiring systemic corticosteroid treatment, or current active interstitial lung disease requiring treatment or clinical intervention. Active gastrointestinal disease or other conditions that may significantly affect the absorption, distribution, metabolism, or excretion of oral vebreltinib, including active ulcerative gastrointestinal lesions, uncontrolled nausea, vomiting or diarrhoea, clinically significant malabsorption syndrome, in·ability to swallow oral medication, or previous major gastrointestinal surgery that may affect drug absorption. Hypersensitivity Known hypersensitivity to vebreltinib, platinum compounds, pemetrexed, gemcitabine, nab-paclitaxel, or any of their excipients, where applicable to the planned treatment regimen. Other serious medical conditions Any serious, uncontrolled, or clinically significant medical condition that, in the investigator's judgement, could increase the risk associated with study treatment, interfere with the interpretation of study results, compromise protocol compliance, or otherwise make the participant unsuitable for the study. This includes, but is not limited to, severe or uncontrolled psychiatric disorders, active primary immunodeficiency, or a history of allogeneic organ transplantation. Pregnancy and lactation Pregnant or breastfeeding women, or women of childbearing potential who are unwilling or unable to use highly effective contraception during the study treatment period and for 3 months after the last dose of study treatment. Other conditions affecting study participation Any other condition or circumstance that, in the investigator's judgement, would make the participant unsuitable for study participation or would compromise participant safety, study compliance, or the integrity of study assessments.
引自 ClinicalTrials.gov, NCT07549061, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07549061,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。